{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:14:49Z","timestamp":1771002889137,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The growing need for symptomatic treatment of post-traumatic neuropathic pain (PTNP) continues\u00a0to be unmet. Studies evaluating the efficacy of pregabalin for reducing neuropathic pain following trauma and surgery yielded positive results over \u2264\u20098-week treatment. To assess the efficacy and tolerability of pregabalin over 3 months in patients with PTNP, a randomized, double-blind, placebo-controlled, parallel-group trial evaluated patients with PTNP at 101 centers in 11 countries\u2014the longest, largest such trial. Adults diagnosed with PTNP were randomly assigned (1:1) to 15 weeks of pregabalin (flexibly dosed 150\u2013600\u00a0mg\/day) or matching placebo. Primary efficacy analysis was by mixed-model repeated measures comparing change from baseline to week 15 in weekly mean pain scores between active and placebo groups. Evaluable patients included 274 in the pregabalin group and 265 in the placebo group. Trauma was surgical in 49.6% of patients, non-surgical in the remainder. The primary efficacy analysis showed no statistically significant difference between pregabalin and placebo groups in the change from baseline to week 15 [mean difference, \u2212\u20090.22 points (95% confidence interval, 0.54\u20130.10); <jats:italic>p<\/jats:italic>\u2009=\u20090.1823]. However, comparisons for key secondary outcome measures yielded <jats:italic>p<\/jats:italic> values\u2009&lt;\u20090.05 favoring pregabalin. Consistent with the known safety profile of pregabalin, the most common adverse events were dizziness and somnolence (14.6 and 9.9% of patients, respectively) with pregabalin (vs 4.2 and 3.4% with placebo). These findings demonstrate the feasibility of conducting a large, phase 3 registration trial in the heterogeneous PTNP study population.<\/jats:p><jats:p><jats:italic>ClinicalTrials.gov<\/jats:italic> NCT01701362.<\/jats:p>","DOI":"10.1007\/s00415-018-9063-9","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T06:09:48Z","timestamp":1537510188000},"page":"2815-2824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial"],"prefix":"10.1007","volume":"265","clinical-trial-number":[{"clinical-trial-number":"nct01701362","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6296-8998","authenticated-orcid":false,"given":"John","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malca","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Gregorian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"issue":"1\u20132","key":"9063_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0304-3959(98)00038-4","volume":"76","author":"IK Crombie","year":"1998","unstructured":"Crombie IK, Davies HT, Macrae WA (1998) Cut and thrust: antecedent surgery and trauma among patients attending a chronic pain clinic. Pain 76(1\u20132):167\u2013171","journal-title":"Pain"},{"issue":"9522","key":"9063_CR2","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S0140-6736(06)68700-X","volume":"367","author":"H Kehlet","year":"2006","unstructured":"Kehlet H, Jensen TS, Woolf CJ (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367(9522):1618\u20131625. https:\/\/doi.org\/10.1016\/S0140-6736(06)68700-X","journal-title":"Lancet"},{"issue":"18","key":"9063_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18):1630\u20131635. https:\/\/doi.org\/10.1212\/01.wnl.0000282763.29778.59","journal-title":"Neurology"},{"issue":"1","key":"9063_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2010.07.031","volume":"152","author":"M Haanpaa","year":"2011","unstructured":"Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko TJ, Rice AS, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD (2011) NeuPSIG guidelines on neuropathic pain assessment. Pain 152(1):14\u201327. https:\/\/doi.org\/10.1016\/j.pain.2010.07.031","journal-title":"Pain"},{"issue":"4","key":"9063_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuron.2012.02.008","volume":"73","author":"CA von Hehn","year":"2012","unstructured":"von Hehn CA, Baron R, Woolf CJ (2012) Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73(4):638\u2013652. https:\/\/doi.org\/10.1016\/j.neuron.2012.02.008","journal-title":"Neuron"},{"issue":"2","key":"9063_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12630-013-0067-8","volume":"61","author":"I Gilron","year":"2014","unstructured":"Gilron I, Kehlet H (2014) Prevention of chronic pain after surgery: new insights for future research and patient care. Can J Anaesth 61(2):101\u2013111. https:\/\/doi.org\/10.1007\/s12630-013-0067-8","journal-title":"Can J Anaesth"},{"issue":"1","key":"9063_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/bja\/aen099","volume":"101","author":"WA Macrae","year":"2008","unstructured":"Macrae WA (2008) Chronic post-surgical pain: 10 years on. Br J Anaesth 101(1):77\u201386. https:\/\/doi.org\/10.1093\/bja\/aen099","journal-title":"Br J Anaesth"},{"issue":"3","key":"9063_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/ALN.0000000000000307","volume":"121","author":"K Wong","year":"2014","unstructured":"Wong K, Phelan R, Kalso E, Galvin I, Goldstein D, Raja S, Gilron I (2014) Antidepressant drugs for prevention of acute and chronic postsurgical pain: early evidence and recommended future directions. Anesthesiology 121(3):591\u2013608. https:\/\/doi.org\/10.1097\/ALN.0000000000000307","journal-title":"Anesthesiology"},{"key":"9063_CR9","unstructured":"Lyrica (pregabalin) [Prescribing Information]. Pfizer Inc. NY, NY (2016) http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=561. Accessed 25 Jan 2018"},{"issue":"8","key":"9063_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1468-1331.2010.02979.x","volume":"17","author":"R van Seventer","year":"2010","unstructured":"van Seventer R, Bach FW, Toth CC, Serpell M, Temple J, Murphy TK, Nimour M (2010) Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 17(8):1082\u20131089. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.02979.x","journal-title":"Eur J Neurol"},{"key":"9063_CR11","unstructured":"US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) (2014) Guidance for industry analgesic indications: developing drug and biological products. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM384691.pdf. Accessed 10 Nov 2017"},{"issue":"6","key":"9063_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","volume":"153","author":"RH Dworkin","year":"2012","unstructured":"Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice AS, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D (2012) Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 153(6):1148\u20131158. https:\/\/doi.org\/10.1016\/j.pain.2012.03.003","journal-title":"Pain"},{"issue":"10","key":"9063_CR13","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R, Gockel U, Tolle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911\u20131920. https:\/\/doi.org\/10.1185\/030079906X132488","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"9063_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ana.10786","volume":"55","author":"R Burstein","year":"2004","unstructured":"Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1):19\u201326. https:\/\/doi.org\/10.1002\/ana.10786","journal-title":"Ann Neurol"},{"issue":"2","key":"9063_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006842-200203000-00008","volume":"64","author":"K Kroenke","year":"2002","unstructured":"Kroenke K, Spitzer RL, Williams JB (2002) The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 64(2):258\u2013266","journal-title":"Psychosom Med"},{"key":"9063_CR16","volume-title":"Columbia-suicide severity rating scale","author":"K Posner","year":"2009","unstructured":"Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, Fisher P, Zelazny J, Burke A, Oquendo M, Mann J (2009) Columbia-suicide severity rating scale. C-SSRS) The Research Foundation for Mental Hygiene, New York"},{"key":"9063_CR17","volume-title":"Measuring functioning and well-being: the medical outcomes study approach","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart A (1992) Measuring functioning and well-being: the medical outcomes study approach. Duke University Press, Durham"},{"key":"9063_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0749-2081(85)80041-3","volume":"1","author":"CS Cleeland","year":"1985","unstructured":"Cleeland CS (1985) Measurement and prevalence of pain in cancer. Semin Oncol Nurs 1:87\u201392","journal-title":"Semin Oncol Nurs"},{"key":"9063_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQo\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"issue":"5","key":"9063_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"9063_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pain.2008.06.024","volume":"138","author":"SN Quessy","year":"2008","unstructured":"Quessy SN, Rowbotham MC (2008) Placebo response in neuropathic pain trials. Pain 138(3):479\u2013483. https:\/\/doi.org\/10.1016\/j.pain.2008.06.024","journal-title":"Pain"},{"issue":"3","key":"9063_CR22","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, Tuchman M, LaMoreaux L, Sharma U (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110(3):628\u2013638. https:\/\/doi.org\/10.1016\/j.pain.2004.05.001","journal-title":"Pain"},{"issue":"1\u20132","key":"9063_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","volume":"109","author":"R Sabatowski","year":"2004","unstructured":"Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M, Study G (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109(1\u20132):26\u201335. https:\/\/doi.org\/10.1016\/j.pain.2004.01.001","journal-title":"Pain"},{"issue":"11","key":"9063_CR24","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","volume":"155","author":"DT Demant","year":"2014","unstructured":"Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155(11):2263\u20132273. https:\/\/doi.org\/10.1016\/j.pain.2014.08.014","journal-title":"Pain"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-018-9063-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:06:07Z","timestamp":1628589967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-018-9063-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9063"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9063-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"15 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The protocol complied with the Declaration of Helsinki (1964), and was reviewed and approved by the institutional review board at each participating center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All participants provided written, informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"JM has participated in advisory boards (Pfizer, Editas Medicine, Flexion Therapeutics, Teva, Quark, Pacira, Inspirion Delivery Sciences, Quartet, Pacira Egalet, Biogen, Nektar, Endo, Immune Pharma, Chromocell, Collegium, Purdue, Novartis, Sanofi, Convergence, Aptinyx, Daiichi Sankyo, Allergan, Plasmasurgical, and Grunenthal), received research funding (Depomed, Pfizer), and served on Data Safety Monitoring Boards (Allergan, Novartis). M Resnick, R Yang, J Scavone, E Whalen, G Gregorian, B Parsons, and L Knapp are employees of Pfizer Inc. S Greenberg was an employee of Pfizer at the time of the study and development of the manuscript. N Katz is employed by Analgesic Solutions, which provided a central eligibility verification service to identify patients with PTNP.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}